Skip to main content
Caplight Logo









Transition Bio, Inc.

Transition Bio, Inc.

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://transitionbio.com/

Last Round

Series A

Jun 2, 2022

Total Funding Raised

$50M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Transition Bio, Inc. is a biotechnology company that operates a drug discovery platform using biophysical sciences and artificial intelligence to map and modulate biomolecular condensates.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

biomolecular condensatesdrug discovery platformAI drug discoveryAI biotechundruggable targetssmall molecule discoverymicrofluidicshigh-throughput screeningdrug discovery collaborationcomputational drug discoveryoncology drug discoveryneurodegenerative diseasedroplet microfluidicsintrinsically disordered proteinsphase separation biologyALS treatment

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Transition Bio, Inc. Comparables

Compare Transition Bio, Inc. with similar companies based on industry and business-model similarity.

Transition Bio, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nereid
89%
Dewpoint Therapeutics
88%
Nuage Therapeutics
85%

Transition Bio, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 2, 2022
SeedSep 1, 2020

Key People

Founding team and executive leadership

Sasha Milshteyn

Founder & CEO

Founding Team

Transition Bio, Inc. Investors

Notable investors and investment history

Transition Bio, Inc. investors
InvestorRounds
Magnetic VenturesSeries A
Taiho VenturesSeries A
Lifeforce CapitalSeries A, Seed
Northpond VenturesSeries A
Cambridge EnterpriseSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors grew 84% MoM, reaching 1.1K.

  • Jun 22, 2026

    Monthly visitors increased 45% MoM.

Transition Bio, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Transition Bio, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Transition Bio, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range7
Year Founded2020
Last FundingJun 2, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?